(S)-1-ethyl-3-(4-(7-(2-hydroxy-2-methylpropyl)-7-methyl-4-morpholino-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenyl)urea | 1260091-24-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-ethyl-3-(4-(7-(2-hydroxy-2-methylpropyl)-7-methyl-4-morpholino-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenyl)urea
• 英文别名: 1-ethyl-3-[4-[(7S)-7-(2-hydroxy-2-methylpropyl)-7-methyl-4-morpholin-4-yl-5H-furo[3,4-d]pyrimidin-2-yl]phenyl]urea
• CAS: 1260091-24-4
• 化学式: C₂₄H₃₃N₅O₄
• 分子量: 455.557
• InChiKey: SOAONDOGFZWZCO-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  109
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (+/-)-7-allyl-7-methyl-5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione 在 sodium periodate 、 四氧化锇 、 四(三苯基膦)钯 、 草酰氯 、 水 、 potassium acetate 、 sodium carbonate 、 二甲基亚砜 、 N-甲基吗啉氧化物 、 三乙胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 54.5h， 生成 (S)-1-ethyl-3-(4-(7-(2-hydroxy-2-methylpropyl)-7-methyl-4-morpholino-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenyl)urea 、 (R)-1-ethyl-3-(4-(7-(2-hydroxy-2-methylpropyl)-7-methyl-4-morpholino-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl)phenyl)urea
  参考文献：
  名称：

  Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine

  摘要：

  A series of inhibitors of mTOR kinase based on a quaternary-substituted dihydrofuropyrimidine was designed and synthesized. The most potent compounds in this series inhibited mTOR kinase with K-i < 1.0 nM and were highly (>100x) selective for mTOR over the closely related PI3 kinases. Compounds in this series showed inhibition of the pathway and antiproliferative activity in cell-based assays. Furthermore, these compounds had excellent mouse PK, and showed a robust PK-PD relationship in a mouse model of cancer.

  DOI：

  10.1021/jm200215y

文献信息

• OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Bergeron Philippe

  公开号：US20100331305A1

  公开（公告）日：2010-12-30

  Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

  公开的是Formula I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物及其药学上可接受的盐，这些化合物在调节PIKK相关激酶信号传导方面很有用，例如mTOR，并用于治疗至少部分由PIKK信号传导途径失调引起的疾病（例如癌症）。
• [EN] OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS PYRIMIDINE FUSIONNÉS À OXO-HÉTÉROCYCLES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010151601A1

  公开（公告）日：2010-12-29

  Disclosed are compounds of Formula (I), including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). Formula (I).
• Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine
  作者：Frederick Cohen、Philippe Bergeron、Elizabeth Blackwood、Krista K. Bowman、Huifen Chen、Antonio G. DiPasquale、Jennifer A. Epler、Michael F. T. Koehler、Kevin Lau、Cristina Lewis、Lichuan Liu、Cuong Q. Ly、Shiva Malek、Jim Nonomiya、Daniel F. Ortwine、Zhonghua Pei、Kirk D. Robarge、Steve Sideris、Lan Trinh、Tom Truong、Jiansheng Wu、Xianrui Zhao、Joseph P. Lyssikatos

  DOI：10.1021/jm200215y

  日期：2011.5.12

  A series of inhibitors of mTOR kinase based on a quaternary-substituted dihydrofuropyrimidine was designed and synthesized. The most potent compounds in this series inhibited mTOR kinase with K-i < 1.0 nM and were highly (>100x) selective for mTOR over the closely related PI3 kinases. Compounds in this series showed inhibition of the pathway and antiproliferative activity in cell-based assays. Furthermore, these compounds had excellent mouse PK, and showed a robust PK-PD relationship in a mouse model of cancer.